Otsuka Reports Positive Phase 3 Visionary Two-Year Egfr Results For Voyxact In Igan
02/07/2026 24:31
BRIEF-Otsuka Holdings Co., Ltd - Otsuka Reports Positive Phase 3 Visionary Two-Year Egfr Results For Voyxact In Igan July 2 (Reuters) - Otsuka Holdings Co., Ltd 4578.T:
OTSUKA HOLDINGS CO., LTD: OTSUKA REPORTS POSITIVE PHASE 3 VISIONARY TWO-YEAR EGFR RESULTS FOR VOYXACT IN IGAN
Source text: ID:nTSsa8f313
Further company coverage: 4578.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug